{"id":"placebo-matching-bms-790052","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL4303322","moleculeType":"Small molecule","molecularWeight":"518.51"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"BMS-790052 targets the NS5A protein of hepatitis C virus, which is essential for viral RNA replication and assembly. By inhibiting NS5A, the drug prevents HCV from multiplying in infected hepatocytes. This mechanism allows for high barrier to resistance when combined with other direct-acting antivirals in combination therapy regimens.","oneSentence":"BMS-790052 is a direct-acting antiviral agent that inhibits hepatitis C virus (HCV) NS5A protein, blocking viral replication.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:27:50.959Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C virus infection (genotype 1)"}]},"trialDetails":[{"nctId":"NCT01425970","phase":"PHASE2","title":"Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2012-05","conditions":"Hepatitis C","enrollment":210},{"nctId":"NCT00663208","phase":"PHASE2","title":"A Multiple Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Genotype 1 Infected Subjects","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2008-05","conditions":"Chronic Hepatitis C","enrollment":167},{"nctId":"NCT01448044","phase":"PHASE3","title":"Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-12","conditions":"Hepatitis C","enrollment":152},{"nctId":"NCT01616524","phase":"PHASE3","title":"Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2012-07","conditions":"Hepatitis C Virus (HCV)","enrollment":880},{"nctId":"NCT01973049","phase":"PHASE3","title":"UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2013-12","conditions":"Hepatitis C","enrollment":202},{"nctId":"NCT01797848","phase":"PHASE3","title":"Efficacy and Safety Evaluation of a Treatment Consisting of Peg Interferon Alfa + Ribavirin + Daclatasvir in HCV Genotype 1 and 4 Treatment naïve Patients","status":"WITHDRAWN","sponsor":"Bristol-Myers Squibb","startDate":"2014-06","conditions":"Hepatitis C","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo matching BMS-790052","genericName":"Placebo matching BMS-790052","companyName":"Bristol-Myers Squibb","companyId":"bristol-myers-squibb","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BMS-790052 is a direct-acting antiviral agent that inhibits hepatitis C virus (HCV) NS5A protein, blocking viral replication. Used for Chronic hepatitis C virus infection (genotype 1).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}